Precigen Net Income 2012-2021 | PGEN

Precigen net income from 2012 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Precigen Annual Net Income
(Millions of US $)
2020 $-171
2019 $-322
2018 $-509
2017 $-117
2016 $-187
2015 $-84
2014 $-82
2013 $-57
2012 $-104
2011 $-99
Precigen Quarterly Net Income
(Millions of US $)
2021-06-30 $-20
2021-03-31 $-17
2020-12-31 $-42
2020-09-30 $-30
2020-06-30 $-43
2020-03-31 $-56
2019-12-31 $-169
2019-09-30 $-54
2019-06-30 $-39
2019-03-31 $-61
2018-12-31 $-340
2018-09-30 $-57
2018-06-30 $-65
2018-03-31 $-46
2017-12-31 $-27
2017-09-30 $-40
2017-06-30 $-19
2017-03-31 $-31
2016-12-31 $-44
2016-09-30 $-29
2016-06-30 $-49
2016-03-31 $-64
2015-12-31 $-33
2015-09-30 $-38
2015-06-30 $-41
2015-03-31 $27
2014-12-31 $19
2014-09-30 $-53
2014-06-30 $-52
2014-03-31 $4
2013-12-31 $-9
2013-09-30 $8
2013-06-30 $-14
2013-03-31 $-43
2012-12-31
2012-09-30 $-26
2012-06-30 $-22
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.965B $0.103B
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43